Serious adverse events
|
Nivolumab + Ipilimumab ECOG PS0-1 |
Nivolumab + Ipilimumab ECOG PS2 |
Nivolumab + Ipilimumab Brain Metastasis |
Nivolumab + Ipilimumab Mucosal |
Nivolumab + Ipilimumab Ocular/Uveal |
Nivolumab + Ipilimumab Cutaneous |
Nivolumab + Ipilimumab Acral |
Nivolumab + Ipilimumab Other |
Total subjects affected by serious adverse events
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
355 / 477 (74.42%) |
33 / 55 (60.00%) |
32 / 42 (76.19%) |
28 / 32 (87.50%) |
47 / 64 (73.44%) |
257 / 365 (70.41%) |
10 / 10 (100.00%) |
47 / 62 (75.81%) |
number of deaths (all causes)
|
169 |
29 |
13 |
20 |
41 |
107 |
6 |
25 |
number of deaths resulting from adverse events
|
|
|
|
|
|
|
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
|
|
|
|
|
Basal cell carcinoma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cancer pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chronic myeloid leukaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Malignant neoplasm progression
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
86 / 477 (18.03%) |
17 / 55 (30.91%) |
15 / 42 (35.71%) |
11 / 32 (34.38%) |
16 / 64 (25.00%) |
59 / 365 (16.16%) |
3 / 10 (30.00%) |
14 / 62 (22.58%) |
occurrences causally related to treatment / all
|
0 / 102 |
0 / 19 |
0 / 16 |
0 / 14 |
0 / 19 |
0 / 67 |
0 / 4 |
0 / 17 |
deaths causally related to treatment / all
|
0 / 51 |
0 / 15 |
0 / 6 |
0 / 8 |
0 / 12 |
0 / 33 |
0 / 3 |
0 / 10 |
Metastases to liver
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metastatic malignant melanoma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Neoplasm malignant
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Prostate cancer
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tumour haemorrhage
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oesophageal squamous cell carcinoma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
|
|
|
|
|
|
Deep vein thrombosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertension
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypotension
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
1 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral arterial occlusive disease
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Shock
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vasculitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vein collapse
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Venous thrombosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
2 / 62 (3.23%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral venous disease
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thrombophlebitis superficial
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
|
|
|
|
|
|
Asthenia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
1 / 365 (0.27%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
1 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chest pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Fatigue
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
5 / 365 (1.37%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
4 / 7 |
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
2 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
General physical health deterioration
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperthermia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Polyserositis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pyrexia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
18 / 477 (3.77%) |
1 / 55 (1.82%) |
2 / 42 (4.76%) |
2 / 32 (6.25%) |
2 / 64 (3.13%) |
14 / 365 (3.84%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
13 / 20 |
0 / 1 |
1 / 2 |
0 / 2 |
1 / 2 |
11 / 16 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Multiple organ dysfunction syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
Non-Cardiac chest pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oedema peripheral
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sudden death
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular stent thrombosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune system disorders
|
|
|
|
|
|
|
|
|
Anaphylactic shock
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cytokine release syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Drug hypersensitivity
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemophagocytic lymphohistiocytosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Autoimmune endocrine disorder
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Eosinophilic granulomatosis with polyangiitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
|
|
|
|
|
|
Metrorrhagia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dysmenorrhoea
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
|
|
|
|
|
Chronic obstructive pulmonary disease
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 477 (1.05%) |
1 / 55 (1.82%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
6 / 365 (1.64%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 6 |
0 / 1 |
0 / 2 |
0 / 0 |
0 / 0 |
2 / 7 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Interstitial lung disease
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
1 / 1 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleural effusion
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
1 / 55 (1.82%) |
2 / 42 (4.76%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
5 / 365 (1.37%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
0 / 2 |
0 / 0 |
0 / 1 |
0 / 6 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleurisy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia aspiration
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Pneumonitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
10 / 477 (2.10%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
2 / 64 (3.13%) |
7 / 365 (1.92%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
8 / 10 |
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
5 / 7 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary embolism
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
5 / 365 (1.37%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 5 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
Pulmonary haematoma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary oedema
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
Respiratory failure
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Immune-Mediated pneumonitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleuritic pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumothorax
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
|
|
|
|
|
|
Anxiety
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Confusional state
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Psychotic disorder
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Organic brain syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Investigations
|
|
|
|
|
|
|
|
|
Alanine aminotransferase increased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
8 / 477 (1.68%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
3 / 64 (4.69%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
8 / 8 |
0 / 0 |
1 / 1 |
1 / 1 |
3 / 3 |
3 / 3 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aspartate aminotransferase increased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
General physical condition abnormal
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 3 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
Liver function test increased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oxygen saturation decreased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Transaminases increased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
4 / 365 (1.10%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
5 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
5 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
White blood cells urine positive
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood bilirubin increased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
C-Reactive protein increased
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
|
|
|
|
|
|
Accidental overdose
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Clavicle fracture
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infusion related reaction
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Overdose
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural fever
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subdural haematoma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Fall
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
|
|
|
|
|
|
Arrhythmia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Atrial fibrillation
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
2 / 42 (4.76%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrial flutter
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular block
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure congestive
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiogenic shock
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Myocardial infarction
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myocarditis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
Stress cardiomyopathy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Supraventricular tachycardia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute myocardial infarction
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac arrest
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery disease
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pericardial effusion
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sinus tachycardia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nervous system disorders
|
|
|
|
|
|
|
|
|
Ataxia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Autoimmune neuropathy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Autonomic neuropathy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Carpal tunnel syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral haemorrhage
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrospinal fluid leakage
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrovascular accident
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
2 / 62 (3.23%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cubital tunnel syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dizziness
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Facial paralysis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Guillain-Barre syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Headache
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 477 (1.47%) |
1 / 55 (1.82%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
7 / 365 (1.92%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
6 / 7 |
0 / 1 |
1 / 1 |
0 / 1 |
0 / 0 |
6 / 7 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intercostal neuralgia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral sensory neuropathy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Petit mal epilepsy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Seizure
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal cord compression
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Syncope
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Central nervous system lesion
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cognitive disorder
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Facial paresis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osmotic demyelination syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Paraplegia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
|
|
|
|
|
|
Agranulocytosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aplastic anaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Autoimmune pancytopenia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Iron deficiency anaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lymphopenia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thrombocytopenia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lymphadenopathy
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
|
|
|
|
|
|
Vertigo
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
|
|
|
|
|
|
Autoimmune uveitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diplopia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Photopsia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Retinal detachment
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cataract
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
|
|
|
|
|
|
Abdominal pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 477 (1.05%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
1 / 64 (1.56%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain upper
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ascites
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Autoimmune colitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
13 / 477 (2.73%) |
1 / 55 (1.82%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
2 / 64 (3.13%) |
7 / 365 (1.92%) |
1 / 10 (10.00%) |
3 / 62 (4.84%) |
occurrences causally related to treatment / all
|
19 / 19 |
1 / 1 |
1 / 1 |
2 / 2 |
4 / 4 |
9 / 9 |
1 / 1 |
4 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chronic gastritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
51 / 477 (10.69%) |
2 / 55 (3.64%) |
2 / 42 (4.76%) |
3 / 32 (9.38%) |
4 / 64 (6.25%) |
39 / 365 (10.68%) |
0 / 10 (0.00%) |
7 / 62 (11.29%) |
occurrences causally related to treatment / all
|
65 / 67 |
2 / 2 |
1 / 2 |
4 / 4 |
6 / 6 |
48 / 50 |
0 / 0 |
9 / 9 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis ulcerative
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Constipation
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diarrhoea
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
35 / 477 (7.34%) |
2 / 55 (3.64%) |
2 / 42 (4.76%) |
1 / 32 (3.13%) |
5 / 64 (7.81%) |
30 / 365 (8.22%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
33 / 40 |
2 / 2 |
2 / 3 |
1 / 1 |
5 / 5 |
28 / 35 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dry mouth
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
3 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enterocolitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal toxicity
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Inguinal hernia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal obstruction
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal perforation
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mouth haemorrhage
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nausea
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
2 / 64 (3.13%) |
4 / 365 (1.10%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
4 / 6 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 2 |
3 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatic failure
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis acute
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rectal haemorrhage
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Small intestinal obstruction
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vomiting
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
2 / 64 (3.13%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
3 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 2 |
2 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal hernia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Autoimmune pancreatitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune-Mediated enterocolitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
9 / 477 (1.89%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
8 / 365 (2.19%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
10 / 10 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
9 / 9 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Retroperitoneal haemorrhage
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
|
|
|
|
|
|
Autoimmune hepatitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
16 / 477 (3.35%) |
1 / 55 (1.82%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
2 / 64 (3.13%) |
13 / 365 (3.56%) |
0 / 10 (0.00%) |
2 / 62 (3.23%) |
occurrences causally related to treatment / all
|
20 / 20 |
2 / 2 |
1 / 1 |
0 / 0 |
2 / 2 |
18 / 18 |
0 / 0 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholestasis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic failure
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
4 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
3 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis acute
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatobiliary disease
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatocellular injury
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
7 / 477 (1.47%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
3 / 32 (9.38%) |
1 / 64 (1.56%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
8 / 9 |
1 / 1 |
0 / 0 |
5 / 5 |
1 / 1 |
2 / 3 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatotoxicity
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
2 / 64 (3.13%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
2 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis acute
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Drug-Induced liver injury
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
4 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
2 / 2 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune-Mediated hepatitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
17 / 477 (3.56%) |
0 / 55 (0.00%) |
2 / 42 (4.76%) |
0 / 32 (0.00%) |
3 / 64 (4.69%) |
11 / 365 (3.01%) |
0 / 10 (0.00%) |
3 / 62 (4.84%) |
occurrences causally related to treatment / all
|
20 / 20 |
0 / 0 |
3 / 3 |
0 / 0 |
3 / 3 |
14 / 14 |
0 / 0 |
3 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
|
|
|
|
|
|
Dermatitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dermatitis allergic
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Drug eruption
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Drug reaction with eosinophilia and systemic symptoms
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Erythema
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lichen planus
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pemphigoid
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Psoriasis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rash
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 477 (1.05%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
4 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
2 / 3 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rash maculo-papular
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
5 / 5 |
0 / 0 |
1 / 1 |
1 / 1 |
0 / 0 |
4 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Stevens-Johnson syndrome
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Toxic skin eruption
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
|
|
|
|
|
|
Acute kidney injury
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
10 / 477 (2.10%) |
0 / 55 (0.00%) |
2 / 42 (4.76%) |
1 / 32 (3.13%) |
1 / 64 (1.56%) |
7 / 365 (1.92%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
4 / 10 |
0 / 0 |
1 / 2 |
0 / 1 |
1 / 1 |
3 / 7 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 0 |
Haematuria
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
Nephritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal failure
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tubulointerstitial nephritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract obstruction
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune-Mediated renal disorder
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
|
|
|
|
|
|
Adrenal insufficiency
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
4 / 365 (1.10%) |
1 / 10 (10.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
6 / 6 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
4 / 4 |
1 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Adrenocortical insufficiency acute
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperthyroidism
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
8 / 477 (1.68%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
8 / 365 (2.19%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
8 / 8 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
8 / 8 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypophysitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
24 / 477 (5.03%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
1 / 32 (3.13%) |
5 / 64 (7.81%) |
15 / 365 (4.11%) |
0 / 10 (0.00%) |
3 / 62 (4.84%) |
occurrences causally related to treatment / all
|
26 / 26 |
0 / 0 |
1 / 1 |
1 / 1 |
5 / 5 |
17 / 17 |
0 / 0 |
3 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypopituitarism
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
3 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
3 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lymphocytic hypophysitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
0 / 55 (0.00%) |
2 / 42 (4.76%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
6 / 365 (1.64%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
6 / 6 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
6 / 6 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Primary adrenal insufficiency
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thyroiditis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thyroiditis acute
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune-Mediated hyperthyroidism
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
|
|
|
|
|
|
Arthralgia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arthritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Back pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
1 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bursitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intervertebral disc degeneration
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intervertebral disc protrusion
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Jaw cyst
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal chest pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pain in extremity
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pathological fracture
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rhabdomyolysis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rheumatic disorder
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal pain
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Muscle disorder
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Muscular weakness
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Polyarthritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Synovial cyst
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
|
|
|
|
|
|
Abscess limb
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Alveolar osteitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis viral
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Campylobacter gastroenteritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cellulitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
4 / 365 (1.10%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Clostridium difficile infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Device related infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Encephalitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocarditis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis infectious
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enterocolitis infectious
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Erysipelas
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal viral infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Herpes zoster
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
1 / 64 (1.56%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 4 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
1 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Influenza
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lower respiratory tract infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 3 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Meningitis aseptic
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pharyngitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumococcal infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumocystis jirovecii pneumonia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
3 / 64 (4.69%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 6 |
0 / 0 |
0 / 1 |
0 / 0 |
1 / 3 |
0 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural cellulitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pyoderma
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory tract infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory tract infection viral
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rhinovirus infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sepsis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 477 (1.05%) |
1 / 55 (1.82%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
5 / 365 (1.37%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 5 |
0 / 1 |
0 / 1 |
0 / 0 |
0 / 0 |
1 / 5 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Septic arthritis streptococcal
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Septic shock
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sinusitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal bacteraemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal sepsis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Upper respiratory tract infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
4 / 477 (0.84%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
1 / 64 (1.56%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
0 / 4 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Viral infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound infection staphylococcal
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal abscess
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
Bacteraemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchopulmonary aspergillosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cns ventriculitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Escherichia urinary tract infection
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lymphangitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 477 (0.00%) |
1 / 55 (1.82%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Meningitis bacterial
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oral candidiasis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osteomyelitis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia klebsiella
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metabolism and nutrition disorders
|
|
|
|
|
|
|
|
|
Dehydration
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes mellitus
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
6 / 477 (1.26%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
5 / 365 (1.37%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
5 / 6 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
4 / 5 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic ketoacidosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Electrolyte imbalance
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypercalcaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperglycaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 477 (1.05%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
4 / 365 (1.10%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
1 / 5 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 4 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperkalaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
1 / 10 (10.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
Hypokalaemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyponatraemia
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
3 / 365 (0.82%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
1 / 3 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ketoacidosis
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 477 (0.63%) |
0 / 55 (0.00%) |
1 / 42 (2.38%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
3 / 3 |
0 / 0 |
1 / 1 |
0 / 0 |
0 / 0 |
2 / 2 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Malnutrition
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
1 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Type 1 diabetes mellitus
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
2 / 42 (4.76%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
1 / 365 (0.27%) |
0 / 10 (0.00%) |
1 / 62 (1.61%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
2 / 2 |
0 / 0 |
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Type 2 diabetes mellitus
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 477 (0.42%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
0 / 32 (0.00%) |
0 / 64 (0.00%) |
2 / 365 (0.55%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 2 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Decreased appetite
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 477 (0.21%) |
0 / 55 (0.00%) |
0 / 42 (0.00%) |
1 / 32 (3.13%) |
0 / 64 (0.00%) |
0 / 365 (0.00%) |
0 / 10 (0.00%) |
0 / 62 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |